Compare QDEL & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | ANAB |
|---|---|---|
| Founded | 1979 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2022 | 2015 |
| Metric | QDEL | ANAB |
|---|---|---|
| Price | $16.22 | $63.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $32.75 | ★ $72.60 |
| AVG Volume (30 Days) | ★ 1.2M | 491.1K |
| Earning Date | 05-06-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.35 | ★ 91.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,730,200,000.00 | $234,603,000.00 |
| Revenue This Year | $3.51 | N/A |
| Revenue Next Year | $3.86 | $33.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $15.08 | $15.40 |
| 52 Week High | $37.24 | $68.39 |
| Indicator | QDEL | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 32.27 | 58.51 |
| Support Level | N/A | $43.67 |
| Resistance Level | $30.65 | $68.39 |
| Average True Range (ATR) | 1.18 | 3.72 |
| MACD | -0.06 | -0.22 |
| Stochastic Oscillator | 16.64 | 63.65 |
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).